HIV coinfection with tuberculosis medical therapy

Revision as of 17:08, 6 December 2012 by Maheep Sangha (talk | contribs) (Created page with "__NOTOC__ {{HIV coinfection with tuberculosis}} {{CMG}} ==Overview== Recommendations for treating tuberculosis in adults with HIV infection are, with a few exceptions, the sa...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

HIV coinfection with tuberculosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating HIV coinfection with tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Prevention

Case Studies

Case #1

HIV coinfection with tuberculosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV coinfection with tuberculosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV coinfection with tuberculosis medical therapy

CDC on HIV coinfection with tuberculosis medical therapy

HIV coinfection with tuberculosis medical therapy in the news

Blogs on HIV coinfection with tuberculosis medical therapy

Directions to Hospitals Treating HIV coinfection with tuberculosis

Risk calculators and risk factors for HIV coinfection with tuberculosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Recommendations for treating tuberculosis in adults with HIV infection are, with a few exceptions, the same as those for adult TB patients who are not HIV infected. However, managing HIV-related TB is complex and people with HIV and TB should seek care from a health care provider or providers with expertise in the management of both HIV disease and TB. Because persons with HIV infection are often taking numerous medications, some of which interact with anti-TB medications, experts in the treatment of HIV-related TB should be consulted.

Role of Treatment

  • Without treatment, as with any other opportunistic infection, HIV and TB can work together to shorten the life of the person infected.
  • Someone with untreated latent TB infection and HIV infection is much more likely to develop active TB disease during his or her lifetime than someone without HIV infection.
  • Among people with latent TB infection, HIV infection is the strongest known risk factor for progressing to active TB disease.
  • A person who has both HIV infection and active TB disease has an AIDS-defining condition.
  • Since viral load is the single greatest risk factor for all modes of HIV transmission, ART use decreases the risk that HIV will be transmitted from one person to another.

Recommended Regimen

The recommended treatment of TB disease in HIV-infected adults (when the disease is caused by organisms that are known or presumed to be susceptible to first-line drugs) is a 6-month regimen consisting of:

For the first 2 months
An initial phase of isoniazid (INH), a rifamycin, pyrazinamide (PZA), and ethambutol (EMB).
For the last 4 months
A continuation phase of INH and a rifamycin.
  • Patients with advanced HIV (CD4 counts < 100/µl) should be treated with daily or three-times-weekly therapy in both the initial and the continuation phases.
  • Twice weekly therapy may be considered in patients with less-advanced immunosuppression (CD4 counts ≥ 100/µl).
  • Once-weekly INH/rifapentine in the continuation phase should not be used in any HIV-infected patient.

Duration of Treatment

Six months
For adults with HIV, even for patients with culture-negative TB.
Nine months (extend continuation phase to 7 months)
For HIV-infected patients with delayed response to therapy (e.g., culture positive after 2 months of treatment).

Drug Interactions

A major concern in treating TB in HIV-infected persons is the interaction of rifampin (RIF) with certain antiretroviral agents (some protease inhibitors [PIs] and nonnucleoside reverse transcriptase inhibitors [NRTIs]).

Rifabutin, which has fewer problematic drug interactions, may be used as an alternative to RIF.

WHO Recommendations

In addition to initiating earlier antiretroviral therapy (ART), WHO recommends the implementation of the Three I's for HIV/TB to reduce the burden of TB among people living with HIV:

  • Intensified TB case finding,
  • Isoniazid preventive therapy,
  • Infection control for TB.

WHO recommends that the Three I's for HIV/TB in addition to ART be part of a TB prevention package and that emphasize that they should be core components of HIV services with AIDS programmes and service providers taking the primary responsibility for the Three I's for HIV/TB.

References

Template:WH Template:WS